Fresenius stock extends its recovery on 2025 earnings strength.

Fresenius (DE0005785604) stock is supported by 2025 revenue of EUR 21.5 billion and adjusted EBITDA of EUR 4.0 billion, while the company also reported adjusted net income of EUR 1.8 billion for the year. Those figures frame the stock on 24 July 2026, even without a fresh event attached to today's session.

EUR 21.5 billion revenue

For 2025, Fresenius reported revenue of EUR 21.5 billion, up 5% at constant currency, according to the company's investor materials. Adjusted EBITDA reached EUR 4.0 billion, and the adjusted EBITDA margin came in at 18.6%, which gives the recovery a margin anchor rather than a pure sales story.

Adjusted net income rose to EUR 1.8 billion in 2025, and management highlighted continued execution across the portfolio. The comparison matters because a 5% constant-currency increase is not just accounting noise; it shows the company still converted top-line growth into operating profit.

Margin at 18.6 percent

The 18.6% adjusted EBITDA margin in 2025 is the cleanest single profitability marker in the latest report set. It also matters because Fresenius has spent recent years simplifying the group structure and lifting operating efficiency across its core businesses.

For investors, the mix of EUR 21.5 billion in revenue, EUR 4.0 billion in adjusted EBITDA and EUR 1.8 billion in adjusted net income is more useful than a generic growth label. It shows the business was large enough to protect profitability while still posting year-on-year expansion.

Care delivery drives scale

Fresenius Kabi and Fresenius Helios remain the company's most visible operating engines, and the 2025 numbers suggest the portfolio still has scale in both treatment and healthcare supply. The group's latest reporting also points to ongoing balance sheet discipline, which investors usually watch alongside margin trends.

The market lens is simple: if revenue keeps rising at a 5% constant-currency pace and EBITDA holds near EUR 4.0 billion, the question becomes whether that can be repeated rather than merely maintained. That is the key comparison after the 2025 set.

Helios and Kabi

Fresenius Helios and Fresenius Kabi are the two product and service pillars that explain most of the group's earnings quality. Their mix of hospital care, clinical nutrition, medicines and infusion therapies still gives Fresenius a broad defensive base.

The latest annual figures indicate that this base translated into EUR 1.8 billion in adjusted net income in 2025, which is the number that matters most after revenue. A healthcare group can post growth, but the stock usually responds best when that growth also reaches the bottom line.

Stock level matters

Fresenius stock remains tied to how the market prices that 2025 profitability set against the company's multi-year turnaround. The shares have to be read against the latest annual earnings and the margin now sitting at 18.6%, not against abstract sector optimism.

At 24 July 2026, the most defensible market read is still built around the reported 2025 numbers: EUR 21.5 billion in revenue, EUR 4.0 billion in adjusted EBITDA and EUR 1.8 billion in adjusted net income. Those are the figures that define the current valuation debate.